Zacks Research Has Positive Estimate for EW FY2024 Earnings

Edwards Lifesciences Co. (NYSE:EW - Free Report) - Research analysts at Zacks Research boosted their FY2024 earnings per share (EPS) estimates for shares of Edwards Lifesciences in a research report issued on Tuesday, January 7th. Zacks Research analyst R. Department now forecasts that the medical research company will earn $2.58 per share for the year, up from their prior forecast of $2.57. The consensus estimate for Edwards Lifesciences' current full-year earnings is $2.56 per share. Zacks Research also issued estimates for Edwards Lifesciences' Q4 2024 earnings at $0.55 EPS, Q2 2026 earnings at $0.67 EPS, Q3 2026 earnings at $0.71 EPS, Q4 2026 earnings at $0.72 EPS and FY2026 earnings at $2.76 EPS.

A number of other equities analysts have also weighed in on EW. The Goldman Sachs Group lifted their price target on shares of Edwards Lifesciences from $81.00 to $90.00 and gave the company a "buy" rating in a report on Thursday, December 5th. Evercore ISI lowered their price target on Edwards Lifesciences from $76.00 to $70.00 and set an "in-line" rating for the company in a research report on Tuesday, October 1st. JPMorgan Chase & Co. upped their price target on Edwards Lifesciences from $72.00 to $78.00 and gave the stock a "neutral" rating in a research note on Friday, October 25th. Morgan Stanley reaffirmed an "equal weight" rating and issued a $70.00 price objective on shares of Edwards Lifesciences in a research note on Friday, October 11th. Finally, Truist Financial reissued a "hold" rating and set a $78.00 target price (up previously from $70.00) on shares of Edwards Lifesciences in a research report on Thursday, December 5th. Sixteen research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average target price of $79.40.

Edwards Lifesciences Trading Down 1.0 %

Edwards Lifesciences stock traded down $0.74 during trading on Friday, reaching $73.41. The company had a trading volume of 3,473,379 shares, compared to its average volume of 3,943,663. Edwards Lifesciences has a 12-month low of $58.93 and a 12-month high of $96.12. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. The stock's 50 day moving average price is $71.64 and its two-hundred day moving average price is $72.19. The firm has a market capitalization of $43.30 billion, a price-to-earnings ratio of 10.59, a PEG ratio of 3.61 and a beta of 1.12.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its quarterly earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.67. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. The firm had revenue of $1.35 billion for the quarter, compared to analyst estimates of $1.57 billion. During the same period last year, the company earned $0.59 EPS. The firm's quarterly revenue was up 8.9% on a year-over-year basis.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the business. FSA Wealth Management LLC acquired a new stake in Edwards Lifesciences in the third quarter worth $30,000. Prospera Private Wealth LLC acquired a new stake in shares of Edwards Lifesciences in the 3rd quarter worth about $32,000. Avior Wealth Management LLC increased its holdings in shares of Edwards Lifesciences by 138.7% in the 3rd quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company's stock worth $35,000 after acquiring an additional 308 shares during the period. HHM Wealth Advisors LLC bought a new stake in Edwards Lifesciences in the 2nd quarter valued at about $55,000. Finally, Peoples Bank KS acquired a new position in Edwards Lifesciences during the 3rd quarter valued at about $40,000. 79.46% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Edwards Lifesciences

In related news, insider Larry L. Wood sold 25,000 shares of the firm's stock in a transaction on Tuesday, November 5th. The stock was sold at an average price of $65.91, for a total transaction of $1,647,750.00. Following the transaction, the insider now directly owns 198,526 shares in the company, valued at $13,084,848.66. This trade represents a 11.18 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the business's stock in a transaction on Wednesday, November 13th. The shares were sold at an average price of $65.57, for a total transaction of $327,850.00. Following the sale, the vice president now owns 46,936 shares of the company's stock, valued at approximately $3,077,593.52. The trade was a 9.63 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 37,500 shares of company stock valued at $2,508,350 in the last three months. Corporate insiders own 1.29% of the company's stock.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.